Simpler Grants.gov #HT942526PRCRPCTA

Army and DHA Seek Clinical Trial Proposals for FY26 Peer Reviewed Cancer Research Program

The Department of the Army, through the U.S. Army Medical Research Acquisition Activity (USAMRAA) and the Defense Health Agency (DHA), is soliciting proposals for the FY26 Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA): - Seeks clinical trial proposals (phase 0 to phase III) focused on cancer types relevant to military health and congressionally directed topics - Supports evaluation of new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and emerging technologies for cancer treatment or management - Requires inclusion of a clinical trial and patient advocate involvement in each proposal - All preclinical work must be completed prior to award start; animal studies are not permitted - Open to a broad range of applicants; no specific OEMs or vendors are named - Approximately $45 million in total funding available, with about 10 awards anticipated - Each award capped at $4.5 million and a maximum period of performance of 4 years - Clinical trials must begin within 12 months of award (or 18 months if regulatory approval is required) - Place of performance and contracting managed by USAMRAA and the Defense Health Agency

Description

The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to significantly impact the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials may evaluate new products, pharmacologic agents, devices, clinical guidance, or emerging technologies, ranging from small proof-of-concept trials to large-scale phase III trials. Applications must include a clinical trial, patient advocates, and all preclinical work must be completed prior to the award start date. Animal studies are not allowed under this award mechanism.

View original listing